Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Study Summary

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions / Drugs

Datopotamab deruxtecan (Dato-DXd)Docetaxel

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment400 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910305+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.